Thiazolidinediones, insulin-sensitizing agents that 18% ( P õ .05, n Å 3 ) . Proliferating VSM cells ( synthetic phenotype ) expressed small amounts of lower insulin and lipid levels in insulin-resistant states, block agonist-induced Ca 2/ entry into a-actin, whereas nonproliferating VSM cells ( contractile phenotype ) 1,2 These drugs have also been shown to lower blood pressure in several animal models of hyhe thiazolidinediones represent a unique class of insulin sensitizing compounds that lower blood glucose, triglycerides, and cholesterol, and that reduce the hyperinsulinpertension 3 -8 and in humans. 9, 10 In studies with cultured rat vascular smooth muscle ( VSM ) cells, thiazolidinediones were recently reported to block L-type Received January 25, 1996. Accepted September 10, 1996 Ca 2/ channels, 11 agonist-induced Ca 2/ entry,
cells and in human coronary artery ( hcaVSM ) VSM rendered quiescent by exposure to growth medium containing 1% FBS for 48 h. This procedure reduced cells. Also, because thiazolidinediones have been shown to promote differentiation in preadipocyte cell proliferation to 3% to 5% of that of cells growing in optimal medium. These mitotically quiescent cells fibroblasts, 14, 15 we determined whether these agents could promote the transition of haVSM cells from the were then stimulated to proliferate by exposure for 16 h to media containing 10% FBS or 1% FBS plus PDGFless differentiated synthetic ( proliferative ) phenotype to the well differentiated metabolic ( contractile ) BB ( final concentration 0.67 nmol/L) and various concentrations of drug. The cells were pulsed with 5 mCi/ phenotype.
mL [ 3 H ] -thymidine ( ICN ) for 5 h and the trichloroace-MATERIALS AND METHODS
tic acid (TCA) insoluble radioactivity determined by liquid scintillation. Chemicals Ciglitazone (5-4-[1-methylcyclohexylmethoxy ) benzyl ] -thiazolidine-2,4-dione ) and troglitazone Cytotoxicity Assay Potential cytotoxic effects of the ([{]-5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-thiazolidinediones were assessed by monitoring the remethoxy ) benzyl ] -thiazolidine-2,4-dione ) were gifts lease of LDH into the medium after exposure of cells from The Upjohn Company ( Kalamazoo, MI ) and to the test compound. The release of LDH is a widely Parke-Davis Pharmaceuticals ( Triangle Park, SC ) , re-used method for determining cytotoxicity and viability spectively. The BB homodimer of platelet-derived in a variety of cell types. 17, 18 Cells in mid-log phase growth factor ( PDGF-BB ) was purchased from US Bio-were incubated with the indicated concentrations of thichemical, fetal bovine serum ( FBS ) was from HyClone azolidinedione for 24 or 72 h, the medium removed, Laboratories, and fluorescein isothiocyanate ( FITC ) -la-and LDH activity measured as a decrease in absorbance beled goat antimouse IgG antibody was from Cappel. at 340 nm upon oxidation of NADH to NAD/ coupled All other chemicals and cell culture media were pur-to reduction of pyruvate. In a positive control ( cells chased from Sigma Chemical Co. Sigma Kit 340-LD was treated with 1% Triton X-100 ) , the amount of LDH reused to assay media for lactate dehydrogenase ( LDH ) leased is proportional to the total number of cells. activity.
Statistical Analyses Data were analyzed for statistical significance by means of Student's t test ( comparison Cell Cultures Cultured VSM cells from human aorta and human coronary artery were used in these studies. between two groups of data sets ) and, where indicated, are presented as the mean { SEM of ''n'' determinaThe haVSM cell line was obtained from American Type Culture Collection ( CRL 1999 ) For these experiments, haVSM cells were plated, grown CA ) and maintained in a proprietary medium conin their optimal medium, and treated with ciglitazone taining 5% FBS, 2 ng /mL human fibroblast growth facas described. Triplicate counts of viable cells were made tor, 10 ng /mL human endothelial growth factor, and for 4 consecutive days, after which the drug was re-0.89 mg/mL dexamethasone. These cells were used at moved and cells counted for an additional 2 days. Cigthe first passage after their receipt from Clonetics Corlitazone inhibited proliferation of haVSM cells in a conporation.
centration-dependent manner, and this inhibitory effect Cell Proliferation The effect of each thiazolidinedi-was evident within 24 h of their exposure to ciglitazone. one on proliferating cells was evaluated by performing The effect of 5 mmol/L ciglitazone was small; however, growth curve analyses. Cells were plated in their re-there was a 65% inhibition ( P õ .05 ) of cell growth on spective optimal growth media and allowed to attach day 3 of exposure to 40 mmol/L ciglitazone ( Figure over a 20 to 24 h period, after which the medium was 1A ) . Removal of ciglitazone resulted in a resumption removed and fresh medium containing various concen-of haVSM cell proliferation at a rate similar to that obtrations of ciglitazone or troglitazone was added. Viable served in untreated cells. The difference between uncell counts based on trypan blue exclusion were treated ( control ) cells and cells pretreated with 40 obtained approximately every 24 h. mmol/L ciglitazone prior to removal of drug, were no longer statistically significant 48 h after removal of drug DNA Synthesis DNA synthesis was determined as ( Figure 1A ) . These data suggest that growth inhibition incorporation of [ 3 H ] -thymidine into cells, as prewas not due to ciglitazone toxicity. viously described. 16 Briefly, cells were plated in 24 well multiwell dishes at 2. Figure 1B ) . The inhibitory effect was significant at 20 mmol/L ciglitazone ( 63% of control, P õ .05 ) , and almost complete at 40 mmol/L, the highest concentration tested ( 91% of control, P õ .01 ) . Because PDGF is the principal mitogenic factor for smooth muscle cell proliferation in the pathogenesis of atherosclerosis, 19, 20 we also examined the effect of ciglitazone on PDGF-stimulated DNA synthesis in haVSM cells. PDGF-BB maximally stimulated DNA synthesis in these cells at concentrations ¢ 0.67 nmol / L ( data not shown ) . Mitotically quiescent haVSM cells were incubated with PDGF-BB ( 0.67 nmol/L) without or with ciglitazone for 16 h, and DNA synthesis assessed by quantifying [ Figure 1C ) . The inhibitory effect was marked at 5 mmol/L ciglitazone ( 34% ) , and significant at 20 mmol/L (P õ .05 ) and 40 mmol/L (P õ .025 ) , suggesting a major effect of ciglitazone on PDGF-stimulated DNA synthesis.
Effect of Ciglitazone on Expression of Smooth Muscle a-Actin in haVSM
The effect of ciglitazone ( 40 mmol/L) on the amount of smooth muscle a-actin expressed in proliferating haVSM cells was evaluated using a monoclonal antibody to smooth muscle a-actin. trol consisted of cells treated with 1% Triton X-100 in order to release total cellular LDH. These detergenttreated cells gave a 20-fold increase in medium-associated LDH activity as compared with the untreated cells ( negative control ) . Thus, on the basis of results obtained from both trypan blue exclusion and LDH release studies, two independent assays of cell viability, neither ciglitazone nor troglitazone had any detectable cytotoxic effect on haVSM or hcaVSM cells at concentrations used in these studies.
DISCUSSION
In this study, we found that thiazolidinediones inhibit growth factor -induced proliferation and DNA synthesis in cultured human aorta and coronary VSM cells. Troglitazone, a thiazolidinedione in the final stages of clinical trials for treatment of NIDDM, caused marked inhibition of human aorta and coronary VSM cells at the lowest concentration tested. Ciglitazone, the prototype thiazolidinedione, inhibited tractant 21, 22 and is a more potent vasoconstrictor than angiotensin II. 23 High levels of PDGF, released by aggregating platelets and secreted by proliferating VSM (5 mmol/L) inhibited haVSM cell proliferation only cells in arteriosclerotic and restenotic lesions in situ, 30% after exposure for a similar period of time ( Figure stimulate neointimal proliferation. 19,20 PDGF exists as 1A ) . Removal of troglitazone resulted in a resumption three dimeric combinations of two chains ( AA, AB of haVSM cell proliferation ( Figure 3A ) and hcaVSM and BB ) , which bind to their cognate receptors ( aa, cell proliferation ( Figure 3B ) to levels not significantly ab and bb ) . PDGF-BB was chosen for these studies different from those in cells never exposed to troglita-for its unique capacity to bind all three types of PDGF zone.
receptors with high affinity. 19, 21, 22 The central role played by PDGF in vessel injury in vivo is supported Cytotoxicity Studies The inhibitory effects of ciglitaby demonstration of increased accumulation of PDGF zone and troglitazone on VSM cell proliferation could B-chain protein in macrophages in all stages of develhave been caused by drug-induced cytotoxicity. Howopment of atherosclerotic lesions in both human and ever, this was unlikely because the percentages of vianonhuman primates. 24 Moreover, infusion of PDGFble cells ( based on trypan blue exclusion ) in cells BB greatly increased ( 20-fold ) the intimal thickening treated with ciglitazone or troglitazone at the concenand migration of VSM cells from the media to the trations used in this study, were the same as the correintima at the site of balloon angioplasty in rats. 22 In sponding untreated ( control ) cells. To confirm these athymic nude mice, administration of polyclonal antifindings, we utilized an independent viability assay body to PDGF inhibits neointimal VSM cell accumulabased on the release of LDH from cells in culture. The tion after angioplasty. 25 Neointimal proliferation of haVSM cells were incubated in optimal growth me-VSM cells is thought to be a critical event in the pathodium containing ciglitazone vehicle ( 0.1% DMSO congenesis of ischemic heart disease, a major cause of trol ) or ciglitazone. At 24 and 72 h, samples of media morbidity and mortality. 19 Thus, PDGF modulation were removed and assayed for LDH activity. There was of VSM cells appears to play a principal role in the no significant difference in LDH activity in media from proliferative component of atherosclerotic and resteuntreated cells 
Myocytes in the vascular wall are capable of pheno-undergoing arterial catheterization, oral administration of troglitazone 35 and pioglitazone 36 resulted in typic transition in response to physical and chemical factors in the cellular milieu. Endothelial denudation significant inhibition of intimal hyperplasia induced by balloon injury. It is of interest to note that troglitafollowing traumatic injury ( as in angioplasty ) or disease ( as in atherosclerosis ) causes disruption of the zone reduced both medial and intimal hyperplasia in the Wistar rats undergoing balloon injury, and the basement membrane. Platelets adhere and aggregate at the site of the lesion, releasing PDGF, TNF-a, and effect was more pronounced in the fatty rat as compared with the lean control.
36
other growth-regulatory factors, mitogens and inflammatory cytokines. 19 Vascular myocytes express a Troglitazone has been evaluated extensively in humans without evidence of adverse effects 9, 10 and is function-dependent continuum between two distinct phenotypes based on the predominance of contractile presently in phase III human trials for treatment of NIDDM. Given the frequent clustering of cardiovas-( metabolic ) versus proliferative ( synthetic ) functions.
26,27 The more differentiated, contractile pheno-cular risk factors in patients with hypertension, it is increasingly recognized that successful management type is characterized by the expression of smooth muscle a-actin, whereas less differentiated, proliferat-of hypertensive patients must involve more than just lowering blood pressure. The observations that thiaing VSM cells are characterized by a down-regulation of smooth muscle a-actin and predominance of the b-zolidinediones lower blood pressure, improve glucose tolerance, and lower lipid levels in humans sugisoform. 28 The mitogens, growth factors, and inflammatory cytokines released at the site of vascular injury gest that these agents may be useful for preventing target organ damage in hypertension. The findings mediate dedifferentiation of VSM cells and conversion of the contractile ( quiescent ) phenotype to the that thiazolidinediones attenuate growth factor-induced proliferation and promote differentiation of synthetic ( proliferative ) phenotype.
26,27 These proliferating cells migrate from the medial layer, and in-human aorta and coronary artery myocytes in vitro, as well as inhibiting intimal hyperplasia in rats in vade and accumulate within the intimal space ( neointimal hyperplasia ) , causing a reduction of the luminal vivo, should further motivate studies on the efficacy of these agents in the management of patients at risk diameter 22, 29 and ultimately restenosis. 30 Because thiazolidinediones have been shown to promote differen-for coronary artery disease or for restenosis after invasive vascular procedures. tiation of preadipocytes, 14, 15 we determined whether these drugs would promote VSM cell differentiation REFERENCES by increasing expression of the a-isoform. Exposure of haVSM cells to ciglitazone resulted in marked 
